CA2875975A1 - Novel iminosugars and their applications - Google Patents

Novel iminosugars and their applications Download PDF

Info

Publication number
CA2875975A1
CA2875975A1 CA2875975A CA2875975A CA2875975A1 CA 2875975 A1 CA2875975 A1 CA 2875975A1 CA 2875975 A CA2875975 A CA 2875975A CA 2875975 A CA2875975 A CA 2875975A CA 2875975 A1 CA2875975 A1 CA 2875975A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
groups
formula
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2875975A
Other languages
English (en)
French (fr)
Inventor
J. L. Kiappes
Peter Laing
Raymond Dwek
Nicole Zitzmann
Stephanie Pollock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
Unither Virology LLC
Original Assignee
University of Oxford
Unither Virology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford, Unither Virology LLC filed Critical University of Oxford
Publication of CA2875975A1 publication Critical patent/CA2875975A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
CA2875975A 2012-06-06 2013-06-05 Novel iminosugars and their applications Abandoned CA2875975A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656265P 2012-06-06 2012-06-06
US61/656,265 2012-06-06
PCT/US2013/044285 WO2013184780A1 (en) 2012-06-06 2013-06-05 Novel iminosugars and their applications

Publications (1)

Publication Number Publication Date
CA2875975A1 true CA2875975A1 (en) 2013-12-12

Family

ID=49712581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2875975A Abandoned CA2875975A1 (en) 2012-06-06 2013-06-05 Novel iminosugars and their applications

Country Status (8)

Country Link
US (1) US8921568B2 (2)
EP (1) EP2858642A4 (2)
JP (1) JP2015518896A (2)
KR (1) KR20150035767A (2)
CN (1) CN104703597A (2)
CA (1) CA2875975A1 (2)
IN (1) IN2014MN02539A (2)
WO (1) WO2013184780A1 (2)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6011902B2 (ja) * 1979-12-27 1985-03-28 日本新薬株式会社 モラノリンの誘導体
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
BR9813508A (pt) 1997-12-11 2000-10-03 Univ Oxford Inibição de replicação viral associada com membrana
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
JP2002536407A (ja) 1999-02-12 2002-10-29 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の治療のための置換−１，５−ジデオキシ−１，５−イミノ−ｄ−グルシトール化合物の使用
AU1840101A (en) 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
KR100847678B1 (ko) 2000-02-11 2008-07-23 리서치 디벨럽먼트 파운데이션 토코페롤, 토코트리에놀, 다른 크로만 및 측쇄 유도체, 및이들의 용도
WO2001060366A1 (en) * 2000-02-14 2001-08-23 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
CN1694696A (zh) 2002-09-23 2005-11-09 牛津大学校委会 亚氨基糖衍生物在抑制离子通道活性中的应用
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US8481571B2 (en) * 2004-05-04 2013-07-09 Academia Sinica Anti-coronavirus compounds
KR100611931B1 (ko) * 2004-09-02 2006-08-11 강경태 광학활성 알콕시알콜 화합물, 이로부터 유도되는 광학활성1,3-페닐렌-비스[4-(4-알콕시)페닐이미노메틸]벤조에이트화합물 및 이들의 제조방법
US8361999B2 (en) * 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
US8975280B2 (en) 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
US20090252785A1 (en) 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
WO2010027996A1 (en) * 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
CA2753195C (en) 2009-02-23 2015-06-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
ES2562635T3 (es) 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus
KR20120059447A (ko) 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
CN102639133B (zh) 2009-06-12 2015-03-11 联合治疗公司 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法
CN102625801B (zh) 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
KR101497194B1 (ko) 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
WO2011028779A1 (en) 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
JP2013512945A (ja) 2009-12-07 2013-04-18 ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード 破骨細胞生成および／または破骨細胞活性化の阻害における使用のためのｎ置換デオキシノジリマイシン化合物

Also Published As

Publication number Publication date
US20130331578A1 (en) 2013-12-12
KR20150035767A (ko) 2015-04-07
IN2014MN02539A (2) 2015-07-24
EP2858642A1 (en) 2015-04-15
WO2013184780A1 (en) 2013-12-12
US8921568B2 (en) 2014-12-30
CN104703597A (zh) 2015-06-10
JP2015518896A (ja) 2015-07-06
EP2858642A4 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
AU2013245756B2 (en) Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2017379059B2 (en) Ionizable cationic lipid for RNa delivery
EP1698629A2 (en) Polyamines and their use in therapy
CA2856742A1 (en) Biodegradable lipids for the delivery of active agents
JP2015518891A (ja) 抗ウイルス化合物の固体形態
JP6688437B1 (ja) ブチルフタリド−テルミサルタン混成物、その調製方法及びその応用
EP2970184A1 (en) Compounds and uses thereof for the modulaton of hemoglobin
HRP20140626A2 (hr) Postupak priprave inhibitora proteaze hiv
KR0160112B1 (ko) 심장보호 작용을 갖는 토코페롤 유사체
CN103387601B (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
FI105550B (fi) Menetelmä terapeuttisesti käyttökelpoisten guanidiinialkyyli-1,1-bisfosfonihappojohdannaisten valmistamiseksi
US12144806B2 (en) Quinolines that modulate SERCA and their use for treating disease
JP2022137094A (ja) グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
US20240101584A1 (en) Targeted delivery of 1,2,4,5 tetraoxane compounds and their uses
US8921568B2 (en) Iminosugars and their applications
MX2008013435A (es) Sintesis y usos de derivados de acido piroglutamico.
US20250099493A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
KR900006132B1 (ko) 젬-디할로-1,8-디아미노-4-아자-옥탄 및 이의 제조방법
JP3029055B2 (ja) 新規なアスコルビン酸誘導体類
ES2843511T3 (es) Métodos para reducir las concentraciones en sangre de triglicéridos, colesterol total y lipoproteínas de baja densidad
WO2005049619A1 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
JP2003104945A (ja) ２，３−ジメトキシ−５−メチル−１，４−ジヒドロキシベンゼン誘導体およびその製造方法
US11679103B2 (en) Multi-targeting agents for Alzheimer's disease therapy
US20140309275A1 (en) Sphingosine Analogs, Compositions, and Methods Related Thereto
WO2003099819A2 (fr) Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180605